From the *The Children’s Hospital at Westmead
†National Centre for Immunisation Research and Surveillance
‡University of Sydney, Sydney, New South Wales, Australia
§Royal Children’s Hospital
¶University of Melbourne
‖Murdoch Children’s Research Institute, Melbourne, Victoria, Australia.
Accepted for publication February 12, 2018.
N.W. is supported by a National Health and Medical Research Council (NHMRC) Career Development fellowship (APP1063629). N.W. has been an investigator on industry supported (GlaxoSmithKline) investigator initiated trials. No personal funds were received during the conduct of these studies. R.B. has worked with several manufacturers of influenza vaccines in an advisory capacity, as a researcher on vaccines and as presenter of academic information at conferences and occasionally as an Advisory Board member. He has received support to travel and attend such conferences and meetings from BioCSL/Seqirus, GlaxoSmithKline, Sanofi, Novartis and Medimmune/Astra Zeneca. Funding and honoraria are paid directly to a research account at The Children’s Hospital at Westmead and are not personally accepted by R.B. The other authors have no conflicts of interest to disclose.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (www.pidj.com).
Address for correspondence: Jean Li-Kim-Moy, National Centre for Immunisation Research & Surveillance (NCIRS), The Children’s Hospital at Westmead, Corner Hawkesbury Road and Hainsworth Street, Westmead NSW 2145, Australia. E-mail: [email protected].
